Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: schizophrenia/schizoaffective disorder. Clear all
Completed Not applicable Interventional Results available

Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia

NCT00936351
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Mindfulness Meditation, Support Group (control)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 10, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Bellflower, California • Garden Grove, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 10, 2026, 10:12 AM EDT
Recruiting Phase 4 Interventional

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT03495024
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions
Varenicline
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 10, 2026, 10:12 AM EDT
Terminated Phase 4 Interventional

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1

NCT00046813
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

NCT00179062
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions
olanzapine versus risperidone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCT00373672
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
armodafinil (Nuvigil), placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 10, 2026, 10:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neurophysiologic Biomarkers for Cognitive Rehabilitation

NCT05945602
View directory record Official record
Conditions
Schizophrenia Spectrum Disorders
Interventions
Neurophysiologic Biomarker Assessments
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01940159
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004, Risperdal® Consta®
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 10, 2026, 10:12 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCT03794076
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Cromoglycate, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 10, 2026, 10:12 AM EDT
Completed No phase listed Observational

Inpatient Evaluation of Adults With Schizophrenia

NCT00001247
View directory record Official record
Conditions
Schizophrenia
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 10, 2026, 10:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Risperidone or Aripiprazole (patients only)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 10, 2026, 10:12 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

NCT00211302
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

NCT01116830
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838, Standard Antipsychotic Therapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 10, 2026, 10:12 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

State Representation in Early Psychosis 2

NCT07834203
View directory record Official record
Conditions
Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 10, 2026, 10:12 AM EDT
Completed No phase listed Observational

Cross-Sectional Iloperidone IVGTT

NCT01686815
View directory record Official record
Conditions
Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance, Glucose Metabolism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 10, 2026, 10:12 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Psychiatric Genotype/Phenotype Project Repository

NCT00762866
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 65 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis

NCT01570972
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCT05779241
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LYN-005, Risperidone
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 10, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

rTMS in First Episode Psychosis

NCT02131129
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
rTMS, Sham Comparator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 10, 2026, 10:12 AM EDT